Navigation Links
UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
Date:10/11/2007

BERKELEY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced results from a Phase 1a clinical study of CD-NP, Nile's selective NPR-B agonist being developed for the treatment of heart failure. The results of this study will be included in the Company's presentation today at the BIO Investor Forum in San Francisco, CA.

"The development of a peptide that has natriuretic and renal effects, with relatively little effect on blood pressure, is a potentially important achievement. The results of this trial in healthy volunteers have confirmed some of the hypotheses developed during the pre-clinical studies. We were particularly interested to see a clear, dose dependent increase in cGMP, which suggests the molecule activates the NPR receptors," commented Dr. Barry Massie, Professor of Medicine, University of California, San Francisco, Chief, Cardiology Section, San Francisco VA Hospital, and member of Nile's scientific advisory board.

Study Design

The Phase 1a study was conducted to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of various doses of CD-NP compared to placebo over a four-hour infusion in 22 healthy volunteers. The study evaluated several pharmacodynamic variables which may translate into safety and efficacy in the heart failure population. Nile measured the effect of CD-NP on systemic blood pressure, urinary flow rate, urinary sodium excretion, serum potassium, renal function and cGMP, a secondary messenger of the target receptor and indicator of in-vivo activity.

Study Results

CD-NP was well tolerated with no serious adverse events and all subjects completed the four-hour infusion of placebo, 10, 17.5 or 25 ng/kg/min of CD-NP.

With respect to clinical and biomarker assessments, CD-NP (placebo, 10, 17.5 and 25 ng/kg/min) increased urine flow rate versus baseline (125%, 53%, 30% and 230% average change, respectively), increa
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 Concord Medical Services Holdings Limited ... ), a leading specialty hospital management solution provider and ... imaging centers in China , today ... Directors declared a special cash dividend of US$0.30 per ... on the Company,s outstanding ordinary shares. The total expense ...
(Date:7/28/2014)... CHAPEL HILL, N.C. , July 28, 2014 /PRNewswire/ ... results of a clinical trial demonstrating that CXL-1427, a ... was well tolerated in healthy volunteers. The company has ... failure in a Phase IIa clinical trial designed to ... as its dosing levels. The Phase I ...
(Date:7/28/2014)... CARLSBAD, Calif. , July 28, 2014  Isis ... following webcast:What:Isis Pharmaceuticals, Second Quarter 2014 Financial Results and ... / 7:30 a.m. PTWhere: www.isispharm.com How:Live on the ... you are unable to participate during the live event, ... a limited time at www.isispharm.com . ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... 2012  Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, ... 2012, at 8:30 AM ET, to discuss its financial ... to issue its quarterly financial results press release before ... To participate in the live conference call, please dial ...
... 2012 Young Innovations, Inc. (NASDAQ: YDNT ) today ... 31, 2012.  Sales for the first quarter of ... reported in the first quarter of 2011. Income from operations increased ... $5.8 million in the first quarter of 2011. Net income increased ...
Cached Medicine Technology:Insmed to Host 2012 First Quarter Earnings Conference Call 2Insmed to Host 2012 First Quarter Earnings Conference Call 3Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 3Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 4
(Date:7/28/2014)... An estimated 68,000 women and men ... and prostate cancers – an aggressive form of the ... other parts of the body, such as the lungs, ... University College of Medicine have developed a compound ... progression by blocking tumor cells from “re-seeding.” Their discovery ...
(Date:7/28/2014)... Dallas, TX (PRWEB) July 28, 2014 ... Madrid vs. AS Roma tickets in Dallas, TX at ... on July 24th in the USA and it is an ... teams from around the world including teams from La Liga, ... 2014 teams that will battle it out on the pitch ...
(Date:7/28/2014)... Ticket Down is a dependable source for ... at the Sun Life Stadium in early September. The ... Brazil has is one that has continues to go on. ... on a consistent basis. The rivalry between South America ... recent 2014 World Cup. To the delight of soccer ...
(Date:7/28/2014)... Steven Reinberg HealthDay Reporter ... have dementia and heart rhythm irregularities are more likely to ... found. In fact, the study of more than 16,000 ... percent more likely to get a pacemaker than those without ... study is why folks with dementia are so much more ...
(Date:7/28/2014)... The Brooke Jackman Foundation ... than 200,000 books to children and families in need ... Brooke’s Cooks, a new initiative designed to promote literacy, ... at-risk children and their families in the New York ... nutrition information workshops, cooking demonstrations and readings. BJF, in ...
Breaking Medicine News(10 mins):Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4
... Pourqui Lab has shed light on the mechanism causing ... , Vertebrae are formed from their embryonic precursors, called ... species, but varies significantly across species. By comparing the ... the team established an understanding of how an organism ...
... to Fully Measure Quality, WASHINGTON, June 18 ... the Centers for Medicare & Medicaid,Services (CMS) for ... newly introduced "five-star" rating system, but urged caution, ... system that relies heavily,on survey data can not ...
... across from its,Plantation Estates community in Mecklenburg County, ... has signed a purchase agreement on a 48-acre ... and South Trade Street in,Matthews, North Carolina. ACTS ... single family homes with additional numbers of,assisted living ...
... 18 /PRNewswire/ - Canada and California, two world,leaders in the ... gain,a better understanding of the role cancer stem cells play ... agreement. Now we are working together across,borders, bringing together the ... to prevent and treat cancer for the benefit of all ...
... (June 18, 2008) -- Teenagers, obesity-related medical complications ... surgery, according to outcomes data presented this week. ... Children,s Hospital of NewYork-Presbyterian and Columbia University Medical ... Endocrine Society,s 90th Annual Meeting in San Francisco. ...
... awards to states in 2007 created more than 350,000 ... those new jobs, and,spurred more than $50 billion in ... NIH Threatens New Health Research, U.S.,Medical Leadership, and State ... Health has a legacy of great medical accomplishments, including,victories ...
Cached Medicine News:Health News:Pourquié Lab uncovers mechanism contributing to appropriate formation of the spine 2Health News:AHCA Emphasizes Quality Improvement in America's Nursing Homes 2Health News:ACTS Retirement-Life Communities Signs Land Purchase Agreement on 48-Acre Site in Matthews, North Carolina 2Health News:Minister Clement, Governor Schwarzenegger Join Forces to Fight Cancer Through Cancer Stem Cell Research 2Health News:Minister Clement, Governor Schwarzenegger Join Forces to Fight Cancer Through Cancer Stem Cell Research 3Health News:Minister Clement, Governor Schwarzenegger Join Forces to Fight Cancer Through Cancer Stem Cell Research 4Health News:Minister Clement, Governor Schwarzenegger Join Forces to Fight Cancer Through Cancer Stem Cell Research 5Health News:Minister Clement, Governor Schwarzenegger Join Forces to Fight Cancer Through Cancer Stem Cell Research 6Health News:Minimally-invasive weight loss surgery improves health and morbidly obese teens 2Health News:Report: NIH and Global Health Research are a Major Boon to All State Economies 2Health News:Report: NIH and Global Health Research are a Major Boon to All State Economies 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: